Skip to main content

Novo Nordisk A/S (N1VO34.SA) Stock Price and Company Information, 2024

Novo Nordisk A/S

N1VO34.SA

Exchange: SA
Currency Brazilian real
Fiscal Year End: December
Sector: Healthcare
Industry: Drug Manufacturers - General
Gic Sector: Health Care
Gic Group: Pharmaceuticals, Biotechnology & Life Sciences
Gic Industry: Biotechnology
Gic Sub Industry: Biotechnology
Home Category: BDR
Is Delisted: False
Description: Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Address: Novo Alle 1, Bagsvaerd, Denmark, 2880
Website: https://www.novonordisk.com
Full Time Employees: 69260
Updated On: 2024-11-05

Highlights

Market Capitalization: 2866304778240
Market Capitalization Mln: 2866304.77
EBITDA: 126561001472
PE Ratio: 37.01
PEG Ratio: 1.65
Book Value: 25.24
Dividend Share: 9.9
Earnings Share: 2.15
Most Recent Quarter: 2024-06-30
Profit Margin: 0.34
Operating Margin TTM: 0.46
Return On Assets TTM: 0.22
Return On Equity TTM: 0.88
Revenue TTM: 258002993152
Revenue Per Share TTM: 57.80
Quarterly Revenue Growth YOY: 0.25
Gross Profit TTM: 148506000000
Diluted Eps TTM: 2.15
Quarterly Earnings Growth YOY: 0.03

Valuation

Trailing PE: 37.01
Forward PE: 26.95
Price Sales TTM: 11.10
Price Book MRQ: 29.41
Enterprise Value: 2861517404391
Enterprise Value Revenue: 12.95
Enterprise Value Ebitda: 24.96

Technicals

Beta: 0.14
52 Week High: 102.57
52 Week Low: 58.01
50 Day MA: 86.84
200 Day MA: 85.91

Splits & Dividends

Forward Annual Dividend Rate: 0.5
Payout Ratio: 0.37
Ex Dividend Date: 2024-08-15
Last Split Factor: 2:1
Last Split Date: 2023-09-20